Kay Seden - Concepedia

Author

Kay Seden

University of Liverpool ORCID

Also Known As

K Seden, K. Seden, Kay Seden

Publications

889

Citations

H-Index

Concepts

All Affiliations

University of Liverpool Royal Liverpool and Broadgreen University Hospital NHS Trust Liverpool School of Tropical Medicine Makerere University Infectious Diseases Institute

About

Kay Seden is an author at University of Liverpool specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	216
2	Pharmacology	3	3	99
3	Public Health	1	1	117
4	Biostatistics	1	1	49
5	Obstetrics	1	1	117

Kay Seden

Publications

711

Citations

H-Index

Page 1

	Year	Citations
Grapefruit-Drug Interactions Kay Seden, Laura Dickinson, Saye Khoo, Drugs	2010	146
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial Kenneth Kintu, Thokozile R. Malaba, Jesca Nakibuka, The Lancet HIV Treatment And PreventionDolutegravir Versus EfavirenzReproductive HealthAntiviral TherapyGynecology	2020	117
Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England Kay Seden, Jamie J Kirkham, Tom Kennedy, BMJ Open	2013	91
New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals Kay Seden, David Back, Saye Khoo Journal of Antimicrobial Chemotherapy	2010	56
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study Thokozile R. Malaba, Irene Nakatudde, Kenneth Kintu, The Lancet HIV	2022	50
Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach Marco Siccardi, Catia Marzolini, Kay Seden, Clinical Pharmacokinetics Drug InteractionsPharmacokinetic Modelling ApproachPharmacological StudyMedicineBoosted Protease Inhibitors	2013	49
Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort Gabriel Kigen, Sylvester Kimaiyo, Winstone Nyandiko, PLoS ONE	2011	49
Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda Adelline Twimukye, Miriam Laker, Eva Agnes Laker Odongpiny, BMC Infectious Diseases	2021	38
Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz Marco Siccardi, Adeniyi Olagunju, Kay Seden, In Silico Pharmacology Dose AdjustmentPharmacokinetic ModelingPharmacodynamicsPharmacologyPhysiologically-based Pharmacokinetic Model	2013	32
British <scp>HIV</scp> Association guidelines for the management of tuberculosis in adults living with <scp>HIV</scp> 2019 Margherita Bracchi, Clare van Halsema, Frank A. Post, HIV Medicine	2019	23

Page 1